CN101766635B - Composite for disintoxicating and sobering - Google Patents
Composite for disintoxicating and sobering Download PDFInfo
- Publication number
- CN101766635B CN101766635B CN200810237327A CN200810237327A CN101766635B CN 101766635 B CN101766635 B CN 101766635B CN 200810237327 A CN200810237327 A CN 200810237327A CN 200810237327 A CN200810237327 A CN 200810237327A CN 101766635 B CN101766635 B CN 101766635B
- Authority
- CN
- China
- Prior art keywords
- glucose
- fructose
- vitamin
- alanine
- glutaminate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 59
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 278
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 188
- 239000008103 glucose Substances 0.000 claims abstract description 187
- 229930091371 Fructose Natural products 0.000 claims abstract description 184
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 184
- 239000005715 Fructose Substances 0.000 claims abstract description 184
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 159
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 156
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 155
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 155
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 155
- 229960003767 alanine Drugs 0.000 claims abstract description 155
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 139
- 229960003104 ornithine Drugs 0.000 claims abstract description 139
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 129
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 80
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 69
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 68
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 68
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 68
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 68
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 68
- 239000007788 liquid Substances 0.000 claims abstract description 43
- 229960003080 taurine Drugs 0.000 claims abstract description 40
- 238000002360 preparation method Methods 0.000 claims abstract description 39
- 229960002989 glutamic acid Drugs 0.000 claims abstract description 35
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 34
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 34
- 229930182821 L-proline Natural products 0.000 claims abstract description 34
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960001948 caffeine Drugs 0.000 claims abstract description 34
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960000304 folic acid Drugs 0.000 claims abstract description 34
- 235000019152 folic acid Nutrition 0.000 claims abstract description 34
- 239000011724 folic acid Substances 0.000 claims abstract description 34
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 34
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 34
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 34
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 34
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 34
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 34
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 34
- 229960002429 proline Drugs 0.000 claims abstract description 34
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 30
- 229930064664 L-arginine Natural products 0.000 claims abstract description 30
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 30
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 242
- 239000000203 mixture Substances 0.000 claims description 212
- 229930003270 Vitamin B Natural products 0.000 claims description 142
- 235000019156 vitamin B Nutrition 0.000 claims description 142
- 239000011720 vitamin B Substances 0.000 claims description 142
- 235000021433 fructose syrup Nutrition 0.000 claims description 129
- 235000013878 L-cysteine Nutrition 0.000 claims description 121
- 239000004201 L-cysteine Substances 0.000 claims description 121
- 238000004519 manufacturing process Methods 0.000 claims description 42
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 33
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 33
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 33
- 229960005261 aspartic acid Drugs 0.000 claims description 33
- 229960000367 inositol Drugs 0.000 claims description 33
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 33
- 239000002994 raw material Substances 0.000 claims description 19
- 238000007796 conventional method Methods 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 306
- 230000000694 effects Effects 0.000 abstract description 69
- 208000007848 Alcoholism Diseases 0.000 abstract description 15
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 abstract description 14
- 201000007930 alcohol dependence Diseases 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 12
- 229930182816 L-glutamine Natural products 0.000 abstract description 11
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 230000000332 continued effect Effects 0.000 abstract 1
- 235000001727 glucose Nutrition 0.000 abstract 1
- 229960002743 glutamine Drugs 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000011716 vitamin B2 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 90
- 238000012360 testing method Methods 0.000 description 57
- 238000000034 method Methods 0.000 description 53
- 230000006378 damage Effects 0.000 description 40
- 150000001299 aldehydes Chemical class 0.000 description 38
- 239000008280 blood Substances 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 34
- 238000005303 weighing Methods 0.000 description 31
- 230000010534 mechanism of action Effects 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 229940009098 aspartate Drugs 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 24
- 239000000463 material Substances 0.000 description 17
- 230000004060 metabolic process Effects 0.000 description 17
- 238000007254 oxidation reaction Methods 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 210000002249 digestive system Anatomy 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 230000003647 oxidation Effects 0.000 description 15
- 230000035622 drinking Effects 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 13
- 210000001156 gastric mucosa Anatomy 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 229920002527 Glycogen Polymers 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 206010019233 Headaches Diseases 0.000 description 10
- 208000013016 Hypoglycemia Diseases 0.000 description 10
- 208000002173 dizziness Diseases 0.000 description 10
- 231100000869 headache Toxicity 0.000 description 10
- 210000000653 nervous system Anatomy 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001133 acceleration Effects 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 7
- 230000002440 hepatic effect Effects 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 206010060766 Heteroplasia Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000005267 amalgamation Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 230000037149 energy metabolism Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 210000004916 vomit Anatomy 0.000 description 6
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 5
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 5
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010000059 abdominal discomfort Diseases 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000004994 reproductive system Anatomy 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 230000003867 tiredness Effects 0.000 description 4
- 208000016255 tiredness Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 3
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000007443 Neurasthenia Diseases 0.000 description 3
- 231100000643 Substance intoxication Toxicity 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 201000011068 alcoholic psychosis Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 208000015606 cardiovascular system disease Diseases 0.000 description 3
- 208000023652 chronic gastritis Diseases 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 210000003792 cranial nerve Anatomy 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 229960002737 fructose Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000004783 oxidative metabolism Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000017443 reproductive system disease Diseases 0.000 description 3
- 208000012201 sexual and gender identity disease Diseases 0.000 description 3
- 208000015891 sexual disease Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002605 anti-dotal effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 208000036654 deficiency anemia Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NHUFMXNVSAWNTO-OJUPNBFJSA-N (3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O NHUFMXNVSAWNTO-OJUPNBFJSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 108010049717 Muscle Form Glycogen Phosphorylase Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- -1 shows ethanol Chemical compound 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composite (B) for disintoxicating and sobering, which is prepared by glucose and fructose, fruit glucose, honey, L-cysteine, L-alanine, L-ornithine, L-glutamine, L-carnitine according to a certain weight range. In order to enable the effect better, one or more of taurine, L-asparaginic acid or L-aspartate, vitamin B1, vitamin B6, caffeine, L-arginine, L-glutamic acid, L-proline, phaseomannite, vitamin B2, nicotinic acid, folic acid, vitamin B12 and pantothenic acid are also added. The composite can be prepared into liquid preparation and electuary. The composite of the invention can be prepared into food and health food. The invention can quickly disintoxicate, sober, eliminate alcoholism symptom and continued effect of alcohol on a human body, and has no side effect.
Description
Technical field
The present invention relates to food, field of health care food, specifically relate to a kind of Dealcoholic sobering-up material.
Background technology
China is a country with deep spirits culture, and " wine " becomes its people already and carries out the indispensable instrument of social activity.Though responsible drinking is good for one's health, can promote understanding; Deepen emotion; But anything all has dual character, and the harm that excessive consumption of alcohol brings for society and human health is also quite serious; The harm of human body is mainly shown as acute alcoholism and the carry over effect after the acute alcoholism due to the disposable excessive consumption of alcohol, the chronic alcoholism that long-term heavy drinking causes.
Ethanol gets into blood rapidly from gastrointestinal absorption, can 100% in 2 hours be absorbed, and wherein 80% is absorbed by duodenum, jejunum, and stomach absorbs 20%, and the ethanol that gets into body is distributed to each tissue of whole body rapidly.The ethanol that absorbs is except that about 2% discharges by urine with in exhaling; All the other all decompose in vivo; Liver is the major organs of alcohol metabolism; Ethanol generates acetaldehyde through ethanol dehydrogenase (ADH) catalysis in the liver, and the aldehyde dehydrogenase (ALDH) of acetaldehyde in hepatic mitochondria further is oxidized to nontoxic acetic acid, finally generates carbon dioxide and energy.
The speed of liver oxidative metabolism ethanol is very slow; Disposable excessive consumption of alcohol; A large amount of ethanol get into the speed that blood surpasses liver oxidative metabolism ethanol; Cause the concentration of ethanol in the blood to raise, cause acute alcoholism (drunk), the main clinical manifestation of acute alcoholism is influence and the hypoglycemic reaction of ethanol to nervous system, digestive system.
After the acute alcoholism, can cause the discomfort of long period, be called carry over effect.Carry over effect refers to after once drunk, occur the long period headache, dizziness, insomnia, weak, tremble, stomach discomfort and feeling sick, even show as hyponoia and mild ataxia etc.
Long-term excessive consumption of alcohol, liver are prone to accumulate poisoning takes place, and cause hepar damnification, and liver function descends, and causes chronic alcoholism, mainly shows as hyperlipemia, alcoholic liver disease etc.
In the ethanol metabolic process in vivo; The source of aldehyde material mainly contains two aspects: the one, and the formaldehyde that is contained in the wine, acetaldehyde, propionic aldehyde etc.; The 2nd, the formaldehyde that alcohols materials such as contained methanol, ethanol, propanol generate through the body oxidation in the wine, acetaldehyde, propionic aldehyde etc., aldehyde material is far longer than the harm of alcohols material to human body to the harm of human body.
Based on the harm of ethanol to human health, ancient Chinese medicine doctor is very paid close attention to, and thus, the food and the medicine of various Dealcoholic sobering-up occurred.At present, have the product of Dealcoholic sobering-up function, focus mostly on, be aided with other Chinese crude drugs or other compositions in being primary raw material with Chinese crude drug with Dealcoholic sobering-up function, through suitable processed, the Dealcoholic sobering-up product of processing.
The present invention is according to ethanol metabolic process in vivo, the acute and chronic harm that human body is caused to ethanol and drunk after carry over effect, develop a kind of product with Dealcoholic sobering-up function.
Summary of the invention
The object of the invention just is to provide a kind of composite for disintoxicating and sobering of Dealcoholic sobering-up better effects if.
The objective of the invention is to realize through following measure:
The present invention is formed by following feedstock production, by weight, and every 100ml:
Any or two kinds of 0.1～5g, L-carnitine 0.05～5g in any 5～60g, L-cysteine 0.1～5g, L-alanine 0.1～5g, L-ornithine or the L-glutaminate in the mixture of glucose and fructose or high fructose syrup or the Mel.
Compositions of the present invention is mainly processed by following raw material, by weight, and every 100ml:
Any or two kinds of 0.5～3g, L-carnitine 0.25～3g in any 10～50g, L-cysteine 0.5～3g, L-alanine 0.5～3g, L-ornithine or the L-glutaminate in the mixture of glucose and fructose or high fructose syrup or the Mel.
Compositions of the present invention is mainly processed by following raw material, by weight, and every 100ml:
Any or two kinds of 1～2g, L-carnitine 0.5～2g in any 15～35g, L-cysteine 1～2g, L-alanine 1～2g, L-ornithine or the L-glutaminate in the mixture of glucose and fructose or high fructose syrup or the Mel.
Compositions of the present invention is also added one or more compositions in the following raw material, by weight, and every 100ml:
Taurine 0.01～5g, L-aspartic acid or L-aspartate 0.1～5g, vitamin B
10.00015～0.02g, vitamin B
60.00015～0.01g, caffeine 0.01～0.1g.
Compositions of the present invention is also added one or more compositions in the following raw material, by weight, and every 100ml:
Taurine 0.05～3g, L-aspartic acid or L-aspartate 0.5～3g, vitamin B
10.0005～0.015g, vitamin B
60.0005～0.008g, caffeine 0.015～0.05g.
The part by weight of glucose and fructose is in the compositions A composition of the present invention:
Glucose: fructose=0.01～0.99: 0.99～0.01.
The part by weight of glucose and fructose is in the compositions A composition of the present invention:
Glucose: fructose=0.2～0.8: 0.8～0.2.
Compositions of the present invention is also added one or more compositions in the following raw material, by weight, and every 100ml:
L-arginine 0.1～5g, L-glutamic acid 0.1～5g, L-proline 0.1～5g, inositol 0.0025～3g, vitamin B
20.00015～0.02g, nicotinic acid 0.002～0.015g, folic acid 0.00006～0.0004g, vitamin B
120.0000005～0.00001g, pantothenic acid 0.0003～0.02g.
Compositions of the present invention is also added one or more in the following raw material, by weight, and every 100ml:
L-arginine 0.5～3g, L-glutamic acid 0.5～3g, L-proline 0.5～3g, inositol 0.05～2g, vitamin B
20.0005～0.015g, nicotinic acid 0.005～0.01g, folic acid 0.0001～0.0003g, vitamin B
120.000001～0.000008g, pantothenic acid 0.002～0.015g.
The present composition is characterised in that it mainly contains following neccessary composition: in the mixture of glucose and fructose or high fructose syrup or the Mel any, any or two kinds, L-carnitine in L-cysteine, L-alanine, L-ornithine or the L-glutaminate.
It is because of glucose has additional blood glucose that the present invention selects glucose, strengthens the activity of ADH and ALDH, the oxidation Decomposition of acceleration of alcohol, and the drainage of acceleration of alcohol promotes the effect of gastric mucosa wound healing.
The speed that glucose absorbs in gastrointestinal is faster than fructose, and the sugariness of glucose is 0.64 times of sweetness of cane sugar.
It is that cause and effect sugar has additional blood glucose that the present invention selects fructose, activation liver function, the activity of enhancing ADH and ALDH, the oxidation Decomposition of acceleration of alcohol, the excretory effect of acceleration of alcohol.
Fructose metabolic process and insulin in vivo is irrelevant.
The speed that fructose absorbs in gastrointestinal is slower than glucose, and the sugariness of fructose is 1.3-1.8 a times of sweetness of cane sugar.
Fructose can not cause the rapid rising of blood sugar level, and its glycogen growing amount is 3 times of glucose, when energy is provided, helps to stablize the level of blood glucose.
Fructose metabolism does not in vivo produce lactic acid, can not cause muscular soreness and taediumvitae, and fructose is allaying tiredness rapidly, body endurance and metabolic effects.
The present invention selects glucose and fructose to mix to be the speed that in gastrointestinal, absorbs because of glucose faster than fructose, and fructose ethanol decomposition in vivo is stronger than glucose.Glucose and fructose associating can effectively prevent and suppress to reduce because of the blood glucose that ethanol obstacle energy metabolism (suppressing the hepatic glycogen heteroplasia) causes; In the whole metabolic process of ethanol; Promptly help stablizing the level of blood glucose; Can effectively strengthen the activity of ADH and ALDH again, the oxidation of acceleration of alcohol, decomposition and drainage also help the healing that promotes the gastric mucosa damage.
The present invention select glucose and fructose to mix also because, the sugariness of fructose be sweetness of cane sugar 1.3-1.8 doubly, sugariness is too high when product sugar concentration is higher, and a kind of sensation of discomfort is arranged when edible, glucose is united with fructose can make the product mouthfeel better.
It is that cause and effect glucose contains glucose and the fructose more than 40% that the present invention selects high fructose syrup, has the effect of glucose and fructose, and its addition is calculated with glucose and fructose.
It is to contain 60～85% glucose and fructose because of Mel that the present invention selects Mel, has the effect of glucose and fructose, and its addition is calculated with glucose and fructose.
The A composition is any in the following raw material in the present composition: the mixture of glucose and fructose, high fructose syrup, Mel.
It is to promote that because of the L-cysteine has ethanol conversion is an acetaldehyde, relieves the effect of alcohol the antidotal effect that the present invention selects the L-cysteine.
It is to promote alcohol metabolism and to the antidotal effect of aldehydes, alleviate the infringement of ethanol to liver that because of the L-alanine has the liver protecting, L-alanine also have the function of eliminating physical fatigue that the present invention selects the L-alanine.
It is the various metabolic functions that have allaying tiredness and enhance hepatocyte because of the L-ornithine that the present invention selects the L-ornithine, and the protection liver plasma membrane is participated in the effect that hepatocyte is repaired.
The present invention select L-glutaminate be because of:
L-glutaminate has the damage of defence gastric mucosa, quickens the gastric mucosa wound healing, alleviates alcoholism; Keep and support the glutathion antioxidation; Defying age improves immunity, and is anticancer; The liver protecting, keep the effect of the normal function of kidney, pancreas, gallbladder, gastric ulcer, chronic gastritis are had good preventing and therapeutical effect.
L-glutaminate has the brain function of improvement, and is anti-melancholy, promotes the effect of cranial nerve, and to the neurasthenia, dysmnesia have good preventing and therapeutical effect.
L-glutaminate has the blood ammonia levels of regulating muscle meat tissue, alleviates the untoward reaction of lactic acid to human body, and alleviating physical fatigue prevents the aged effect of muscle.
The present invention selects L-ornithine and L-alanine to unite to be can significantly strengthen the Detoxication to ethanol, aldehydes because of L-ornithine and the associating of L-alanine; Obviously alleviate the infringement of ethanol, aldehydes, improve protection effect each system to airframe systems such as digestive system, nervous system, cardiovascular system, reproductive system.
The present invention selects L-glutaminate and L-alanine to unite to be can significantly strengthen the Detoxication to ethanol, aldehydes because of L-glutaminate and the associating of L-alanine; Obviously alleviate the infringement of ethanol, aldehydes, improve protection effect each system to airframe systems such as digestive system, nervous system, cardiovascular system, reproductive system.
It is can significantly strengthen the Detoxication to ethanol, aldehydes because of L-ornithine, L-glutaminate and the associating of L-alanine that the present invention selects L-ornithine, L-glutaminate and L-alanine to unite; Obviously alleviate the infringement of ethanol, aldehydes, improve protection effect each system to airframe systems such as digestive system, nervous system, cardiovascular system, reproductive system.
It is because of the L-carnitine has the promotion fat oxidation that the present invention selects the L-carnitine, and blood lipid regulation effectively reduces lactic acid concn in the blood, and alleviating physical fatigue promotes the effect of spermioteleosis.
The inventor to ethanol acute and chronic harm that the intravital metabolic process of machine and ethanol cause human body and drunk after carry over effect; Different effects mechanism according to glucose and fructose, L-cysteine, L-alanine, L-ornithine, L-glutaminate, L-carnitine; Through the synergism between each composition different effects mechanism; Compositions of the present invention is had fast relieves the effect of alcohol, sobers up, effectively eliminate acute and chronic harm that ethanol causes human body and drunk after carry over effect.
Acute alcoholism is because disposable excessive consumption of alcohol; A large amount of ethanol get into the speed that blood surpasses liver oxidative metabolism ethanol; Cause the concentration of ethanol in the blood to raise; Follow the rising of blood alcohol concentration, show alcoholism symptom in various degree, main clinical manifestation is influence and the hypoglycemic reaction of ethanol to nervous system, digestive system.Wherein, Ethanol shows mainly that to neural influence ethanol obstacle energy metabolism (suppress hepatic glycogen heteroplasia) causes hypoglycemic reaction that hypoglycemia causes and ethanol, aldehydes to neural coup injury, and ethanol mainly shows ethanol, the aldehydes coup injury to digestive system such as liver, stomaches to the influence of digestive system.Therefore, reduce BAC, stabilised blood sugar level, alleviate ethanol, aldehydes is to alleviate the first-selected approach of ethanol to human harm to the coup injury of nervous system and digestive system.
The present invention realizes effectively reducing the purpose of BAC through the mechanism of action of glucose and fructose or high fructose syrup or Mel L-cysteine, L-alanine, alleviates the coup injury of ethanol to nervous system and digestive system.
The present invention is through the mechanism of action of glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine, L-ornithine, L-glutaminate; Especially associating through L-alanine and L-ornithine or L-alanine and L-glutaminate or L-alanine and L-ornithine, L-alanine synergism; Realize the purpose of the thorough conversion of aldehyde material, alleviate the coup injury of aldehydes nervous system and digestive system.
The present invention is through the mechanism of action of glucose and fructose or high fructose syrup or Mel; Especially pass through the joint synergy of glucose and fructose; Realize the purpose of effective stabilised blood sugar level, avoid the hypoglycemic reaction that causes because of ethanol obstacle energy metabolism (suppressing the hepatic glycogen heteroplasia).
The present invention is through the mechanism of action of L-alanine, L-ornithine, L-glutaminate; Especially associating through L-alanine and L-ornithine or L-alanine and L-glutaminate or L-alanine and L-ornithine, L-alanine synergism; Realize protection, keep the normal of liver function to liver.
The present invention realizes the protection to gastric mucosa through the mechanism of action of glucose, L-glutaminate, promotes the regeneration and the reparation of gastric mucosa, reaches the purpose of protection stomach.
Carry over effect after drunk refer to some people after once drunk, have the long period headache, dizziness, have a sleepless night, tremble, stomach discomfort and feel sick, weak, show as hyponoia and mild ataxia sometimes.
Headache, dizzy, to have a sleepless night, tremble be because the neurological symptom that ethanol obstacle energy metabolism (suppressing the hepatic glycogen heteroplasia) causes due to the hypoglycemia brain tissue impairment and ethanol indirectly, aldehydes that the coup injury of cerebral tissue is shown.Hyponoia and mild ataxia are because the neurological symptom that ethanol, aldehydes show the coup injury of cerebral tissue.Feel sick, vomiting is because the gastrointestinal symptom that ethanol shows the coup injury of digestive system.Weak is (to suppress the hepatic glycogen heteroplasia) because the energy metabolism of ethanol obstacle and cause due to the hypoglycemia the too high organism fatigue symptom that shows of lactic acid concn in the blood.
The present invention realizes effective stabilised blood sugar level through the mechanism of action of glucose and fructose or high fructose syrup or Mel, avoids causing because of hypoglycemia the indirect injury of cerebral tissue; The mechanism of action through glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine realizes effectively reducing BAC, makes ethanol obtain oxidation Decomposition completely, alleviates ethanol to neural coup injury; The mechanism of action through glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine, L-ornithine, L-glutaminate realizes the thorough conversion of aldehyde material, alleviates aldehydes to neural coup injury.Through the mechanism of action of L-glutaminate, realize to improving brain function, anti-melancholy, promote cranial nerve, improve the neurasthenia, improve dysmnesia, nervous system such as protection brain.The present invention through above-mentioned four kinds of mechanism removed headache, dizziness after drunk effectively, had a sleepless night, trembled, hyponoia and mild ataxia symptom.
The present invention realizes effectively reducing BAC through the mechanism of action of glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine, alleviates the coup injury of ethanol to digestive system; The mechanism of action through glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine, L-ornithine, L-glutaminate realizes the thorough conversion of aldehyde material, alleviates the coup injury of aldehydes to digestive system.Through the mechanism of action of glucose, L-glutaminate, realize protection to gastric mucosa, promote the regeneration and the reparation of gastric mucosa.The present invention has removed stomach discomfort and nauseating symptom after drunk effectively through above-mentioned three kinds of mechanism.
The present invention realizes reducing lactic acid concn in the blood through the mechanism of action of fructose, L-alanine, L-ornithine, L-glutaminate, L-carnitine, eliminates the weak purpose that waits fatigue symptom.
Ethanol mainly is that liver generation accumulate poisoning causes hepar damnification owing to long-term excessive consumption of alcohol to the chronic hazard of human body, and liver function descends, and mainly shows as hyperlipemia, alcoholic liver disease.
In addition, ethanol also shows as chronic gastritis to the chronic hazard of human body, nervous system disease such as cerebral lesion, alcoholic psychosis, dementia, cancer, cardiovascular system diseases such as alcoholic cardiomyopathy, reproductive system diseases such as ovary damage, sexual disorder.
The alcoholic liver disease that ethanol causes the chronic hazard of human body comprises that hepatocyte is accumulated fatty liver, hepatitis, liver cirrhosis and the hepatocarcinoma that the damage back occurs due to ethanol and the acetaldehyde; Therefore; The major measure of prevention alcoholic liver disease is to reduce the blood concentration of alcohol, make ethanol obtain oxidation Decomposition completely, and ethanol and acetaldehyde accumulating in vivo avoided in the thorough conversion of aldehyde material; Prevention ethanol, acetaldehyde are accumulated damage to hepatocellular, the liver protecting and liver function normally.
The present invention is through the mechanism of action of glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine; Realize effectively reducing BAC; Make ethanol obtain oxidation Decomposition completely, avoid ethanol accumulating in vivo, prevention ethanol is to the damage of accumulating of digestive system; The mechanism of action through glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine, L-ornithine, L-glutaminate; Realize the thorough conversion of aldehyde material; Avoid aldehydes accumulating in vivo, the prevention aldehydes is to the damage of accumulating of digestive system.Through the mechanism of action of L-alanine, L-ornithine, L-glutaminate, realize protection to liver, keep the normal of liver function.The present invention effectively prevents the generation of alcoholic liver disease through above-mentioned three kinds of mechanism.
The mechanism of action of the present invention through the L-carnitine realizes promoting fat oxidation and metabolism, and blood lipid regulation reaches the purpose of prophylaxis of hyperlipidemia.
The present invention realizes the protection to gastric mucosa through the mechanism of action of glucose, L-glutaminate, promotes the regeneration of gastric mucosa and repairs the protection to gastric mucosa, reaches the purpose of prevention chronic gastritis.
Nervous system disease such as the cerebral lesion that ethanol causes the chronic hazard of human body, alcoholic psychosis, dementia cause due to the hypoglycemia brain tissue impairment and ethanol indirectly, aldehydes accumulating due to the damage at cerebral tissue mainly due to ethanol obstacle energy metabolism (suppressing the hepatic glycogen heteroplasia).
The present invention realizes effective stabilised blood sugar level through the mechanism of action of glucose and fructose or high fructose syrup or Mel, avoids causing because of hypoglycemia the indirect injury of cerebral tissue; The mechanism of action through glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine; Realize effectively reducing BAC; Make ethanol obtain oxidation Decomposition completely, avoid ethanol accumulating in vivo, prevention ethanol is accumulated damage to neural; The mechanism of action through glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine, L-ornithine, L-glutaminate; Realize the thorough conversion of aldehyde material; Avoid aldehydes accumulating in vivo, the prevention aldehydes is accumulated damage to neural.Through the mechanism of action of L-glutaminate, realize to improving brain function, anti-melancholy, promote cranial nerve, improve the neurasthenia, improve dysmnesia, nervous system such as protection brain.Nervous system disease such as the cerebral lesion that the present invention causes the chronic hazard of human body through above-mentioned four kinds of mechanism prevention ethanol, alcoholic psychosis, dementia.
The cancer that ethanol causes the chronic hazard of human body comprises the cancer of hepatocarcinoma, oral cancer, pharyngeal cancer, laryngeal carcinoma, esophageal carcinoma, rectal cancer, cancer of pancreas, breast carcinoma, leukemia and brain; Prove through scientific experiments; Ethanol itself does not have directly carcinogenic effect, and aldehyde material contained and that produce in the metabolic process in vivo has the effect of bringing out cancer in the wine.The present invention is through the mechanism of action of glucose and fructose or high fructose syrup or Mel, L-cysteine, L-alanine, L-ornithine, L-glutaminate; Realize the thorough conversion of aldehyde material; Avoid aldehydes accumulating in vivo; Improve the immunocompetence and the anti-cancer ability of body through L-glutaminate, the various cancers that prevention ethanol causes the chronic hazard of human body.
The cardiovascular system diseases such as alcoholic cardiomyopathy that ethanol causes mainly due to ethanol, aldehydes the chronic hazard of human body; Long-term excessive potable spirit can cause the lasting damage and the high triglyceride mass formed by blood stasis of arteries endothelium, thereby causes and quicken the generation of atherosclerosis.Experimentation proof ethanol can make myocardial cell that obvious histology is taken place and metabolic changes.Ethanol makes cardiac muscle downright bad, interstitial fibrosis and sarolemma and mitochondrion occur and changes etc.The metabolite acetaldehyde of ethanol suppresses the vigor of myophosphorylase, influences the oxidative phosphorylation and the proteinic synthetic K in fatty oxidation, the destruction cell that reaches of myocardial cell
+-Na
+-ATP enzyme pump, cause that myocardial cell contractile protein-actin and myosin take off coupling and join, hinder its picked-up Ca
2+Above-mentioned toxic effect of ethanol can cause arrhythmia and myocardium expansion, hypertension, coronary atherosclerotic heart disease, cardiac insufficiency etc.The present invention is through reduce ethanol in blood concentration effectively; Make ethanol obtain oxidation Decomposition completely; Aldehyde material is thoroughly transformed, avoid ethanol and aldehydes accumulating in vivo, prevention is because the cardiovascular system diseases such as alcoholic cardiomyopathy that ethanol, aldehydes cause.Through the mechanism of action of L-carnitine, realize promoting fat oxidation and metabolism, blood lipid regulation, prevention coronary atherosclerotic heart disease, hypertension.Through the mechanism of action of fructose, L-alanine, L-ornithine, L-glutaminate, L-carnitine, realize strengthening the function of heart, the prevention arrhythmia enlarges cardiac insufficiency with cardiac muscle.
Reproductive system diseases such as the ovary damage that ethanol causes the chronic hazard of human body, sexual disorder are mainly due to ethanol, aldehydes accumulating due to the damage reproductive system.The present invention is through reduce ethanol in blood concentration effectively; Make ethanol obtain oxidation Decomposition completely; Aldehyde material is thoroughly transformed, avoid ethanol and aldehydes accumulating in vivo, reproductive system diseases such as the ovary damage that prevention ethanol causes the chronic hazard of human body, sexual disorder.Through L-alanine, L-carnitine reinforcement sexual organ's function, to realize the purpose of preventative function reduction.
For making the present composition reach better effect, also add taurine, L-aspartic acid or L-aspartate, vitamin B in the present composition
1, vitamin B
6, in the caffeine one or more, the further effect of each mechanism of enhancing composition, thus further strengthen the effect of the present composition, make the effect of the present composition better.
It is to promote digesting and assimilating of human body lipid material because of taurine has that the present invention selects taurine, participates in the bile salt metabolism, the liver protecting; Prevent fatty liver and liver cirrhosis, strengthen myocardial contraction, arrhythmia; Prevent congestive heart failure, bring high blood pressure down, alleviate the damage of ethanol gastric mucosa; Increase the gastric mucosa blood flow, anti-blood lactic acid accumulation, the effect of allaying tiredness.
It is because of L-aspartic acid or L-aspartate have the generation that strengthens the intracellular energy of metabolism regulating liver-QI that the present invention selects L-aspartic acid or L-aspartate, promotes the hepatocellular reparation of damage, promotes biliary drainage; Can quicken the resynthesis of ATP in the muscle, phosphagen and glycogen; Regulate glycogen, prevent fatigue, can change glutamic acid into; Strengthen central nervous excitation, strengthen the effect of will.
The present invention selects vitamin B
1Be because of vitamin B
1Oxidation Decomposition with acceleration of alcohol, the intermediate supersession of carbohydrate in participant's somatic cell prevents that acetone acid is poisoned in the body; The stimulating gastrointestinal wriggling promotes the food emptying, appetite stimulator; The function that keeps nervous system, muscle, heart, allaying tiredness, diuretic actions.
The present invention selects vitamin B
6Be because of vitamin B
6Oxidation Decomposition with acceleration of alcohol is participated in the metabolism of vivo acid, participates in the metabolism of glycogen and fatty acid, prevents fatty liver and liver cirrhosis, the effect that glycogen transforms in catalysis muscle and the liver.
It is because of low dose of caffeine has excited higher nervous center that the present invention selects caffeine, inspires enthusiasm, and accelerates blood circulation, reduces fatigue, the effect of excited heart and diuresis (drainage of acceleration of alcohol).
For making the present composition reach better effect, also add L-arginine, L-glutamic acid, L-proline, inositol, vitamin B in the present composition
2, nicotinic acid, folic acid, vitamin B
12, in the pantothenic acid one or more, the further effect of each mechanism of enhancing composition, thus further strengthen the effect of the present composition, make the effect of the present composition better.
It is because of the L-arginine has the free radical resisting damage of the cardiac muscular tissue of enhancing that the present invention selects the L-arginine, alleviates the hardened formation of fatty liver regulating liver-QI, promotes wound healing, the effect of human body immunity improving power.
It is because of L-glutamic acid has enhancing immunity that the present invention selects L-glutamic acid, liver-protective effect.
It is because of the L-proline has enhancing immunity that the present invention selects the L-proline, the liver protecting, the effect of arteriosclerosis.
It is because of inositol has blood lipid regulation that the present invention selects inositol, liver-protective effect.
The present invention selects vitamin B
2Be because of vitamin B
2Have biological oxidation and energy generation in the body of participation, improve the effect of body the environmental emergency adaptive capacity.
The present invention select nicotinic acid (vitamin PP) be because of nicotinic acid as nadide and coenzyme II important composition composition, have saccharide, protein, the lipometabolic effect participated in.
It is because of folic acid has the nutritional anemia of improvement that the present invention selects folic acid, and prevention erythrocyte anemia is participated in the effect of nucleic acid and amino acid metabolism.
The present invention selects vitamin B
12Be because of vitamin B
12Have the nutritional anemia of improvement, guarantee the effect of nucleic acid, proteinic homergy.
The present invention select pantothenic acid be because of pantothenic acid be that the synthetic and degraded of fatty acid, membrane phospholipid are synthetic, the essential composition of amino-acid oxidase degraded.
The inventor further realizes the object of the invention through following measure.
The inventor tests in a large number the consumption of each composition of the present invention and gropes, and draws each composition consumption infra column weight weight range present composition and has effect preferably:
The weight consumption scope of present composition neccessary composition (every 100ml) is:
Any or two kinds of 0.1～5g, L-carnitine 0.05～5g in any 5～60g, L-cysteine 0.1～5g, L-alanine 0.1～5g, L-ornithine or the L-glutaminate in the mixture of glucose and fructose or high fructose syrup or the Mel.
The weight consumption scope of present composition neccessary composition (every 100ml) also is:
Any or two kinds of 0.5～3g, L-carnitine 0.25～3g in any 10～50g, L-cysteine 0.5～3g, L-alanine 0.5～3g, L-ornithine or the L-glutaminate in the mixture of glucose and fructose or high fructose syrup or the Mel.
Preferable amount (every 100ml) is:
Any or two kinds of 1～2g, L-carnitine 0.5～2g in any 15～35g, L-cysteine 1～2g, L-alanine 1～2g, L-ornithine or the L-glutaminate in the mixture of glucose and fructose or high fructose syrup or the Mel.
For making the present composition reach better effect, the A composition is by in the following raw material any in the present composition: the mixture of glucose and fructose, high fructose syrup, Mel.
The part by weight of glucose and fructose is in the compositions A composition of the present invention:
Glucose: fructose=0.01～0.99: 0.99～0.01.
The part by weight of glucose and fructose also is preferably in the compositions A composition of the present invention:
Glucose: fructose=0.2～0.8: 0.8～0.2.
For making the present composition reach better effect, one or more the weight consumption scope (every 100ml) of also adding in the present composition in the following inessential composition is:
Taurine 0.01～5g, L-aspartic acid or L-aspartate 0.1～5g, vitamin B
10.00015～0.02g, vitamin B
60.00015～0.01g, caffeine 0.01～0.1g.
One or more the weight consumption scope (every 100ml) of also adding in the present composition in the following inessential composition is:
Taurine 0.05～3g, L-aspartic acid or L-aspartate 0.5～3g, vitamin B
10.0005～0.015g, vitamin B
60.0005～0.008g, caffeine 0.015～0.05g.
For making the present composition reach better effect, one or more the weight consumption scope (every 100ml) of also adding in the present composition in the following inessential composition is:
L-arginine 0.1～5g, L-glutamic acid 0.1～5g, L-proline 0.1～5g, inositol 0.0025～3g, vitamin B
20.00015～0.02g, nicotinic acid 0.002～0.015g, folic acid 0.00006～0.0004g, vitamin B
120.0000005～0.00001g, pantothenic acid 0.0003～0.02g.
One or more the weight consumption scope (every 100ml) of also adding in the present composition in the following inessential composition is:
L-arginine 0.5～3g, L-glutamic acid 0.5～3g, L-proline 0.5～3g, inositol 0.05～2g, vitamin B
20.0005～0.015g, nicotinic acid 0.005～0.01g, folic acid 0.0001～0.0003g, vitamin B
120.000001～0.000008g, pantothenic acid 0.002～0.015g.
Compositions of the present invention adopts conventional method to be prepared into liquid preparation, electuary.
The compositions of the present invention's preparation can be added food additive, also can not add food additive.
The compositions of preparation according to the invention can be prepared into food, health food.
The present composition has fast and relieves the effect of alcohol, sobers up, and eliminates alcoholism symptom and the ethanol effect to the human body carry over effect.
The composition of the present composition is the nutritional labeling of needed by human body, and therefore, the present composition has no side effect.
Above-mentioned purpose should be regarded as several in the more relevant key property of just oblatio the present invention; Use by different way and perhaps revise obtainable other the useful result of the present invention in disclosed by the invention; Also in scope disclosed by the invention, can not be used to limit protection scope of the present invention.
The present invention sets forth the beneficial effect that the present invention has through following experimental example.
Test Example 1 liquid preparation of the present invention is to the effect of rat blood alcohol concentration
1.1 experiment material
1.1.1 tried thing: liquid preparation of the present invention (embodiment 1).The human body recommended amounts of being tried thing is (inferior) 100ml/ people every day (body weight is by 60 kilograms), is equivalent to 1.67ml/Kg.d.w.
1.1.2 the dosage design: establish blank, basic, normal, high four groups, wherein basic, normal, high three groups are dose groups, and its dosage is respectively 1.67ml/Kg.d.w, 8.33ml/Kg.d.w, 16.7ml/Kg.d.w, is equivalent to 1,5,10 times of human body recommended amounts.
1.1.3 laboratory animal
The healthy rat that Zhengzhou University's animal center provides, body weight 150～200g.
1.2 experimental technique
1.2.1 after 18～24 hours, be divided into four groups, i.e. blank group, basic, normal, high dose groups, every group of 10 rats to the rat fasting of 40 body weight 150～200g.
1.2.2 the blank group is taken normal saline, basic, normal, high dose groups is taken liquid preparation 1.67ml/Kg.d.w of the present invention, 8.33ml/Kg.d.w, 16.7ml/Kg.d.w respectively.
1.2.3 after laboratory animal is taken 1 hour, take 3.00g/Kg.d.w ethanol (using distilled water diluting dehydrated alcohol concentration is 50%) for every rat.
1.2.4 after taking ethanol, took a blood sample from the Mus tail at 0.25,0.5,0.75,1,2,4,6,8,10,12 hour respectively.
1.2.5 institute's blood sampling is handled at once, except that behind the deproteinize, use the gas Chromatographic Determination BAC, Fig. 1 is seen in the variation of laboratory animal BAC.
1.3 experimental result
Visible from the result of Fig. 1, experimental group is compared with matched group, and the BAC of experimental group significantly reduces, and is dosage and relies on trend.Can obviously promote alcohol metabolism from the data acknowledgement liquid preparation of the present invention of experiment gained, significantly reduce BAC.
Test Example 2 liquid preparations of the present invention are to the effect of human blood alcohol concentration
2.1 receive the selection of test product and testing crew
2.1.1 receive test product: liquid preparation 100ml/ bottle of the present invention (embodiment 1).
2.1.2 the selection of testing crew
Select for use the age 35 to 55 years old, body weight 60Kg (± 5%), the heart, liver, renal function are normal, and detecting through medical science does not have 12 unusual male.The testing crew exclusion standard:
A, hepatic insufficiency person promptly surpass clinical normal range of person;
B, allergy, gastrointestinal tract, kidney, liver, HDH person are arranged;
C, alcoholism or drug intoxication medical history person are arranged;
D, begin preceding 2 weeks of test to take medicament persons orally;
E, basic capacity for liquor are lower than 200ml person;
F, other persons of being not suitable for.
2.2 test method
2.2.1 the experimenter was beginning to test the alcoholic food of fasting preceding 3 days; Fasting in test preceding 8 hours of the same day; The food of edible identical type in experimental period.
2.2.2 according to random double blind test; Drank preceding 30 minutes, will receive test product and comfort article, (make receive test product basic identical with color and luster, the mouthfeel of comforting article) is respectively charged in the cup in the same way; Let 6 experimenters drink liquid preparation 100ml of the present invention, 6 experimenters drink comfort article 100ml.
2.2.3 let the experimenter drink 52 degree Luzhou Old Cellar Chinese liquor 200ml in the clock time at 30 minutes during test.
2.2.4 the experimenter was drinking back 4 hours in, and other any beverages of No drinking and edible any food per hour are provided about 200ml water except that restricted.
2.2.5 the experimenter takes a blood sample once before drinking, and drinks back each blood sampling in 0.25,0.5,0.75,1,2,4,6,8,10,12 hour once.
2.2.6 institute's blood sampling is handled at once, behind the removal protein, is used the gas Chromatographic Determination alcohol concentration.
2.2.7 test after 15 days and test (personnel that drink the comfort article drink liquid preparation of the present invention, and the personnel that drink liquid preparation of the present invention drink the comfort article, carry out above-mentioned experiment again) alternately.
2.2.8 Fig. 2 is seen in the variation of experimenter's BAC.
2.3 result of the test
Visible by Fig. 2 result, drink and compared with drinking the comfort article by test product, drink the BAC that receives the test product group and be starkly lower than the BAC of drinking comfort article group.Can obviously promote alcohol metabolism from the data acknowledgement liquid preparation of the present invention of test gained, significantly reduce BAC.
Test Example 3 liquid preparations of the present invention are to people's capacity for liquor and drunk carry over effect and the influence of the time of sobering up
3.1 receiving test product and testing crew selects
3.1.1 receive test product: liquid preparation 100ml/ bottle of the present invention (embodiment 1).
3.1.2 the selection of testing crew
Select for use the age 35 to 55 years old, body weight 60Kg (± 5%), the heart, liver, renal function are normal, and detecting through medical science does not have 20 unusual male.The testing crew exclusion standard:
A, hepatic insufficiency person promptly surpass clinical normal range of person;
B, allergy, gastrointestinal tract, kidney, liver, HDH person are arranged;
C, alcoholism or drug intoxication medical history person are arranged;
D, begin preceding 2 weeks of test to take medicament persons orally;
E, basic capacity for liquor are lower than 200ml or are higher than 300ml person;
F, other persons of being not suitable for.
3.2 test method
3.2.1 the experimenter was beginning to test the alcoholic food of fasting preceding 3 days; Unified dietary standards in test preceding 8 hours of the same day; Food in the edible identical type of duration of test.
3.2.2 according to random double blind test; Drank preceding 30 minutes, will receive test product and comfort article, (make receive test product basic identical with color and luster, the mouthfeel of comforting article) is respectively charged in the cup in the same way; Let 10 experimenters drink liquid preparation 100ml of the present invention, 10 experimenters drink comfort article 100ml.
The speed 3.2.3 drink
Let the experimenter drink 52 degree Luzhou Old Cellar Chinese liquor 100ml in per 30 minutes, one of listed symptom person stops to drink in the drunk criterion of all appearance, the record drinking amount.
3.2.4 the experimenter is stopping to drink back 4 hours in, and other any beverages of No drinking per hour are provided about 200ml water except that restricted.
3.2.5 drunk criterion
(1) words are many;
(2) boast;
(3) pale complexion;
(4) stomach discomfort;
(4) words and deeds are rough;
(5) above-mentioned symptom appears and after, be reluctant to stop the alcohol user.
3.2.6 be arranged in the experimenter in comfortable, the quiet environment and have a rest, note observing their situation at any time, the impression of inquiring them, and make to sober up record.
3.2.7 judge the standard of sobering up: sense of discomfort and carry over effect that all are drunk are eliminated fully, and health returns to the preceding state of drinking fully.
3.2.8 test after 15 days and test (personnel that drink the comfort article drink liquid preparation of the present invention, and the personnel that drink liquid preparation of the present invention drink the comfort article, carry out above-mentioned experiment again) alternately.
3.2.9 result of the test is seen table 1,2,3 (seeing accompanying drawing for details).
Table 1 liquid preparation of the present invention is to the influence of people's drinking amount (n=20, X ± S)
Table 2 liquid preparation of the present invention is to the influence (n=20) of the drunk back of people carry over effect
Annotate: significantly headache, dizziness, weak, to feel sick, vomit, next day, uncomfortable note was 2 minutes; Slight headache, dizziness, weak, to feel sick, vomit, next day, uncomfortable note was 1 minute; No headache, dizziness, weak, to feel sick, vomit, next day, uncomfortable note was 0 minute.
3.3 result of the test
Can know that according to table 1,2,3 result drinking liquid preparation of the present invention can on average increase the alcohol user
Drink liquid preparation of the present invention before table 3 wine to the influence of the time of sobering up (n=20, X ± S)
Capacity for liquor 153.3ml; The average shortening sobered up 7.9 hours time; Drunk back health next day does not almost have sense of discomfort, and appetite next day, appetite are normal, full of vitality.Sober up the time from capacity for liquor and shortening that the data acknowledgement present composition of test gained can not only obviously increase the alcohol user, can also thoroughly eliminate the carry over effect after drunk.
Drink liquid preparation of the present invention after Test Example 4 is drunk to the influence of carry over effect with the time of sobering up
4.1 receiving test product and testing crew selects
4.1.1 receive test product: liquid preparation 100ml/ bottle of the present invention (embodiment 1).
4.1.2 the selection of testing crew
Select for use the age 35 to 55 years old, body weight 60Kg (± 5%), the heart, liver, renal function are normal, and detecting through medical science does not have 20 unusual male.The testing crew exclusion standard:
A, hepatic insufficiency person promptly surpass clinical normal range of person;
B, allergy, gastrointestinal tract, kidney, liver, HDH person are arranged;
C, alcoholism or drug intoxication medical history person are arranged;
D, begin preceding 2 weeks of test to take medicament persons orally;
E, basic capacity for liquor are lower than 200ml or are higher than 300ml person;
F, other persons of being not suitable for.
4.2 test method
4.2.1 the experimenter was beginning to test the alcoholic food of fasting preceding 3 days; Unified dietary standards in test preceding 8 hours of the same day; Food in the edible identical type of duration of test.
The speed 4.2.2 drink
Let the experimenter drink 52 degree Luzhou Old Cellar Chinese liquor 100ml in per 30 minutes, one of listed symptom person stops to drink in the drunk criterion of all appearance.
4.2.3 according to random double blind test; Receive test product and comfort article in the same way (make receive test product basic identical) with color and luster, the mouthfeel of comforting article be respectively charged in the cup; Let 10 to stop the alcohol user and drink liquid preparation 100ml of the present invention, 10 stop the alcohol user and drink comfort article 100ml.
4.2.4 the experimenter is stopping to drink back 4 hours in, and other any beverages of No drinking per hour are provided about 200ml water except that restricted.
4.2.5 drunk criterion
(1) words are many;
(2) boast;
(3) pale complexion;
(4) stomach discomfort;
(4) words and deeds are rough;
(5) above-mentioned symptom appears and after, be reluctant to stop the alcohol user.
4.2.6 be arranged in the experimenter in comfortable, the quiet environment and have a rest, note observing their situation at any time, the impression of inquiring them, and make to sober up record.
4.2.7 judge the standard of sobering up: sense of discomfort and carry over effect that all are drunk are eliminated fully, and health returns to the preceding state of drinking fully.
4.2.8 test after 15 days and test (personnel that drink the comfort article drink liquid preparation of the present invention, and the personnel that drink liquid preparation of the present invention drink the comfort article, carry out above-mentioned experiment again) alternately.
4.2.9 result of the test is seen table 4,5.
Drink liquid preparation of the present invention after table 4 is drunk to carry over effect influence (n=20)
Annotate: significantly headache, dizziness, weak, to feel sick, vomit, next day, uncomfortable note was 2 minutes; Slight headache, dizziness, weak, to feel sick, vomit, next day, uncomfortable note was 1 minute; No headache, dizziness, weak, to feel sick, vomit, next day, uncomfortable note was 0 minute.
4.3 result of the test
Result according to table 4, table 5 can know, drinks liquid preparation of the present invention and can on average shorten the 7.2 hours time of sobering up; Drunk back health next day does not almost have sense of discomfort, and appetite next day, appetite are normal, full of vitality.
Drink liquid preparation of the present invention after table 5 is drunk to the time effects of sobering up (n=20, X ± S)
Can not only obviously shorten the time of sobering up from the data acknowledgement present composition of test gained, can also thoroughly eliminate the carry over effect after drunk.
Description of drawings
Fig. 1 is the influence curve figure of the present invention to the rat blood alcohol concentration.
Fig. 2 is the influence curve figure of the present invention to the human blood alcohol concentration.
The specific embodiment
The present invention combines following examples, comes further to set forth in detail the specific embodiment of the present invention.
Embodiment first
Embodiment 1
1, take by weighing each 125g of glucose and fructose, it is dissolved in the 500ml water, fully stirring makes it to dissolve fully, promptly gets solution I;
2, take by weighing L-cysteine 15g, it is dissolved in the 100ml water, fully stirring makes it to dissolve fully, promptly gets solution II;
3, take by weighing L-alanine 15g, L-ornithine 10g, L-glutaminate 10g, L-carnitine 15g, it is dissolved in the 200ml water, fully stirring makes it to dissolve fully, promptly gets solution III;
4, solution I, II, III are merged, moisturizing makes the amalgamation liquid cumulative volume to 1000ml, after the filtration it is divided in 10 bottles, sterilizes, and promptly processes the liquid preparation of the present composition.
Explain: drink preceding at every turn or drink after drink 100～200ml.
Embodiment 2
1, take by weighing each 100g of glucose and fructose, subsequent use;
2, take by weighing L-cysteine 15g, L-alanine 25g, L-glutaminate 25g, L-carnitine 10g, taurine 15g, subsequent use;
3, the above-mentioned raw materials mix that takes by weighing is even, be distributed into 10 bags (or bag), sterilize, promptly process the electuary of the present composition.
Explain: drink preceding at every turn or drink after 1～2 bag (or bag) of taking after mixing it with water.
Embodiment 3
1, take by weighing glucose 180g, fructose 120g, it is dissolved in the 500ml water, fully stirring makes it to dissolve fully, promptly gets solution I;
2, take by weighing L-cysteine 15g, L-alanine 15g, L-ornithine 20g, L-carnitine 10g, it is dissolved in the 200ml water, fully stirring makes it to dissolve fully, promptly gets solution II;
3, solution I, II are merged, moisturizing makes the amalgamation liquid cumulative volume to 1000ml, after the filtration it is divided in 10 bottles, sterilizes, and promptly processes the liquid preparation of the present composition.
Explain: drink preceding at every turn or drink after drink 100～200ml.
Embodiment 4
1, take by weighing glucose 120g, fructose 180g, subsequent use;
2, take by weighing L-cysteine 15g, L-alanine 15g, L-ornithine 10g, L-glutaminate 10g, L-carnitine 10g, subsequent use;
3, the above-mentioned raw materials mix that takes by weighing is even, be distributed into 10 bags (or bag), sterilize, promptly process the electuary of the present composition.
Explain: drink preceding at every turn or drink after 1～2 bag (or bag) of taking after mixing it with water.
1, take by weighing glucose 50g, fructose 200g, it is dissolved in the 500ml water, fully stirring makes it to dissolve fully, promptly gets solution I;
2, take by weighing L-cysteine 20g, L-alanine 25g, L-glutaminate 20g, L-carnitine 10g, taurine 10g, it is dissolved in the 200ml water, fully stirring makes it to dissolve fully, promptly gets solution II;
3, take by weighing vitamin B
10.1g, vitamin B
60.05g, it is dissolved in the 100ml water, fully stirring makes it to dissolve fully, promptly gets solution III;
4, solution I, II, III are merged, moisturizing makes the amalgamation liquid cumulative volume to 1000ml, after the filtration it is divided in 10 bottles, sterilizes, and promptly processes the liquid preparation of the present composition.
Explain: drink preceding at every turn or drink after drink 100～200ml.
1, take by weighing glucose 40g, fructose 160g, subsequent use;
2, take by weighing L-cysteine 20g, L-alanine 25g, L-ornithine 10g, L-glutaminate 15g, L-carnitine 10g, taurine 15g, subsequent use;
3, take by weighing vitamin B
10.1g, vitamin B
60.05g, subsequent use;
4, the above-mentioned raw materials mix that takes by weighing is even, be distributed into 10 bags (or bag), sterilize, promptly process the electuary of the present composition.
Explain: drink preceding at every turn or drink after 1～2 bag (or bag) of taking after mixing it with water.
1, take by weighing high fructose syrup 300g, it is dissolved in the 500ml water, fully stirring makes it to dissolve fully, promptly gets solution I;
2, take by weighing L-cysteine 15g, L-alanine 15g, L-ornithine 20g, L-carnitine 10g, it is dissolved in the 200ml water, fully stirring makes it to dissolve fully, promptly gets solution II;
3, take by weighing vitamin B
10.1g, vitamin B
60.05g, it is dissolved in the 100ml water, fully stirring makes it to dissolve fully, promptly gets solution III;
4, solution I, II, III are merged, moisturizing makes the amalgamation liquid cumulative volume to 1000ml, after the filtration it is divided in 10 bottles, sterilizes, and promptly processes the liquid preparation of the present composition.
Explain: drink preceding at every turn or drink after drink 100～200ml.
Embodiment 8
1, take by weighing fruit grape sugar 250g, it is dissolved in the 400ml water, fully stirring makes it to dissolve fully, promptly gets solution I;
2, take by weighing L-cysteine 10g, L-alanine 25g, L-glutaminate 15g, L-carnitine 10g, taurine 20g, it is dissolved in the 200ml water, fully stirring makes it to dissolve fully, promptly gets solution II;
3, take by weighing vitamin B
10.1g, vitamin B
60.05g, it is dissolved in the 100ml water, fully stirring makes it to dissolve fully, promptly gets solution III;
4, solution I, II, III are merged, moisturizing makes the amalgamation liquid cumulative volume to 1000ml, after the filtration it is divided in 10 bottles, sterilizes, and promptly processes the liquid preparation of the present composition.
Explain: drink preceding at every turn or drink after drink 100～200ml.
Embodiment 9
1, take by weighing high fructose syrup 200g, subsequent use;
2, take by weighing L-cysteine 15g, L-alanine 25g, L-ornithine 10g, L-glutaminate 15g, L-carnitine 10g, taurine 20g, subsequent use;
3, take by weighing vitamin B
10.1g, vitamin B
60.05g, subsequent use;
4, the above-mentioned raw materials mix that takes by weighing is even, be distributed into 10 bags (or bag), sterilize, promptly process the electuary of the present composition.
Explain: drink preceding at every turn or drink after 1～2 bag (or bag) of taking after mixing it with water.
1, take by weighing Mel 300g it is dissolved in the 400ml water, fully stirring makes it to dissolve fully, promptly gets solution I;
2, take by weighing L-cysteine 10g, L-alanine 15g, L-ornithine 10g, L-glutaminate 15g, L-carnitine 10g, taurine 10g, it is dissolved in the 200ml water, fully stirring makes it to dissolve fully, promptly gets solution II;
3, take by weighing vitamin B
10.1g, vitamin B
60.05g, it is dissolved in the 100ml water, fully stirring makes it to dissolve fully, promptly gets solution III;
4, solution I, II, III are merged, moisturizing makes the amalgamation liquid cumulative volume to 1000ml, after the filtration it is divided in 10 bottles, sterilizes, and promptly processes the liquid preparation of the present composition.
Explain: drink preceding at every turn or drink after drink 100～200ml.
The embodiment second portion
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 5g; B:L-cysteine 0.1g; C:L-alanine 0.1g; D:L-glutamine 0.1g; E:L-carnitine 0.05g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 60g; B:L-cysteine 5g; C:L-alanine 5g; D:L-glutamine 5g; E:L-carnitine 5g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 13
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 40g; B:L-cysteine 2.5g; C:L-alanine 2.5g; D:L-glutamine 2.5g; E:L-carnitine 2.5g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 14
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 10g; B:L-cysteine 0.5g; C:L-alanine 0.5g; D:L-glutamine 0.5g; E:L-carnitine 0.25g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 15
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 50g; B:L-cysteine 3g; C:L-alanine 3g; D:L-glutamine 3g; The mixture of E:L-carnitine 3g glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 16
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 30g; B:L-cysteine 1.8g; C:L-alanine 1.8g; D:L-glutamine 1.8g; E:L-carnitine 1.7g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 17
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 15g; B:L-cysteine 1g; C:L-alanine 1g; D:L-glutamine 1g; E:L-carnitine 0.5g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 18
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 35g; B:L-cysteine 2g; C:L-alanine 2g; D:L-glutamine 2g; E:L-carnitine 2g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 19
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 25g; B:L-cysteine 1.5g; C:L-alanine 1.5g; D:L-glutamine 1.5g; E:L-carnitine 1.3g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 20
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: glucose and fructose 20g; B:L-cysteine 1.5g; C:L-alanine 1.5g; D:L-glutamine 1.5g; E:L-carnitine 1.3g.The mixture of glucose and fructose can replace with high fructose syrup or Mel, and L-glutaminate can use the L-ornithine to replace or both are shared, and method for preparing is with other embodiment.
Embodiment 21
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel (specifically can be 5,12,34,46,60g etc.); B:L-cysteine 0.1～5g (specifically can be 0.1,0.9,2.4,3.8,5g etc.); C:L-alanine 0.1～5g (specifically can be 0.1,1.3,2.7,4.1,5g etc.); Any or two kinds of 0.1～5g (specifically can be 0.1,0.9,1.8,3.7,5g etc.) in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g (specifically can be 0.05,1.6,2.5,3.8,5g etc.); F: taurine 0.01g, L-aspartic acid or aspartate 0.1g, vitamin B
10.00015g, vitamin B
60.00015g, among the caffeine 0.01g any one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel (specifically can be 10,12,26,39,50g etc.); B:L-cysteine 0.5～3g (specifically can be 0.5,1.1,2.3,2.8,3g etc.); C:L-alanine 0.5～3g (specifically can be 0.5,0.9,1.8,2.6,3g etc.); Any or two kinds of 0.5～3g (specifically can be 0.5,0.7,1.4,2.3,3g etc.) in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3 (specifically can be 0.25,0.98,1.3 .2.7,3g etc.) g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35 (specifically can be 15,18,24,31,35g etc.) g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g (specifically can be 1,1.1,1.3,1.4,1.8,2g etc.); C:L-alanine 1～2g (specifically can be 1,1.2,1.3,1.5,2g etc.); Any or two kinds of 1～2g (specifically can be 1,1.2,1.5,1.7,2g etc.) in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g (specifically can be 0.5,0.9,1.6,1.8,2g etc.).
When the value range of certain composition occurring among other each embodiment, i.e. can be in the value range of the being explained any value of expression as present embodiment.Enumerate concrete numerical value no longer one by one at this.The method for preparing of each embodiment is basic identical, repeats no more here.
Embodiment 22
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 5g, L-aspartic acid or aspartate 5g, vitamin B
10.02g, vitamin B
60.01g, among the caffeine 0.1g any one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 23
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 2.5g, L-aspartic acid or aspartate 2.5g, vitamin B
10.01g, vitamin B
60.005g, among the caffeine 0.05g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～1.5g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 24
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 0.05g, L-aspartic acid or aspartate 0.5g, vitamin B
10.0005g, vitamin B
60.0005g, among the caffeine 0.015g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 25
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 3g, L-aspartic acid or aspartate 3g, vitamin B
10.015g, vitamin B
60.008g, among the caffeine 0.05g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 26
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 1.5g, L-aspartic acid or aspartate 1.5g, vitamin B
10.008g, vitamin B
60.004g, among the caffeine 0.025g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 27
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F:L-arginine 0.1g, L-glutamic acid 0.1g, L-proline 0.1g, inositol 0.0025g, vitamin B
20.00015g, nicotinic acid 0.002g, folic acid 0.00006g, vitamin B
120.0000005g, among the pantothenic acid 0.0003g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 28
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F:L-arginine 5g, L-glutamic acid 5g, L-proline 5g, inositol 3g, vitamin B
20.02g, nicotinic acid 0.015g, folic acid 0.0004g, vitamin B
120.00001g, among the pantothenic acid 0.02g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 29
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F:L-arginase 12 .5g, L-glutamic acid 2.5g, L-proline 2.5g, inositol 1.5g, vitamin B
20.01g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000005g, among the pantothenic acid 0.01g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 30
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F:L-arginine 0.5g, L-glutamic acid 0.5g, L-proline 0.5g, inositol 0.05g, vitamin B
20.0005g, nicotinic acid 0.005g, folic acid 0.0001g, vitamin B
120.000001g, among the pantothenic acid 0.002g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 31
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F:L-arginine 3g, L-glutamic acid 3g, L-proline 3 g, inositol 2g, vitamin B
20.015g, nicotinic acid 0.01g, folic acid 0.0003g, vitamin B
120.000008g, among the pantothenic acid 0.015g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 32
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F:L-arginine 1.8g, L-glutamic acid 1.8g, L-proline 1.8g, inositol 1g, vitamin B
20.008g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000004g, among the pantothenic acid 0.008g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 33
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 0.01g, L-aspartic acid or aspartate 0.1g, vitamin B
10.00015g, vitamin B
60.00015g, among the caffeine 0.01g any one or more; G:L-arginine 0.1g, L-glutamic acid 0.1g, L-proline 0.1g, inositol 0.0025g, vitamin B
20.00015g, nicotinic acid 0.002g, folic acid 0.00006g, vitamin B
120.0000005g, among the pantothenic acid 0.0003g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 34
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 0.01g, L-aspartic acid or aspartate 0.1g, vitamin B
10.00015g, vitamin B
60.00015g, among the caffeine 0.01g any one or more; G:L-arginine 5g, L-glutamic acid 5g, L-proline 5g, inositol 3g, vitamin B
20.02g, nicotinic acid 0.015g, folic acid 0.0004g, vitamin B
120.00001g, among the pantothenic acid 0.02g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 35
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 0.01g, L-aspartic acid or aspartate 0.1g, vitamin B
10.00015g, vitamin B
60.00015g, among the caffeine 0.01g any one or more; G:L-arginase 12 .5g, L-glutamic acid 2.5g, L-proline 2.5g, inositol 1.5g, vitamin B
20.01g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000005g, among the pantothenic acid 0.01g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 36
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 5g, L-aspartic acid or aspartate 5g, vitamin B
10.02g, vitamin B
60.01g, among the caffeine 0.1g one or more; G:L-arginine 0.1g, L-glutamic acid 0.1g, L-proline 0.1g, inositol 0.0025g, vitamin B
20.00015g, nicotinic acid 0.002g, folic acid 0.00006g, vitamin B
120.0000005g, among the pantothenic acid 0.0003g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 37
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 5g, L-aspartic acid or aspartate 5g, vitamin B
10.02g, vitamin B
60.01g, among the caffeine 0.1g one or more; G:L-arginine 5g, L-glutamic acid 5g, L-proline 5g, inositol 3g, vitamin B
20.02g, nicotinic acid 0.015g, folic acid 0.0004g, vitamin B
120.00001g, among the pantothenic acid 0.02g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 38
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 5g, L-aspartic acid or aspartate 5g, vitamin B
10.02g, vitamin B
60.01g, among the caffeine 0.1g one or more; G:L-arginase 12 .5g, L-glutamic acid 2.5g, L-proline 2.5g, inositol 1.5g, vitamin B
20.01g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000005g, among the pantothenic acid 0.01g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 39
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 2.5g, L-aspartic acid or aspartate 2.5g, vitamin B
10.01g, vitamin B
60.005g, among the caffeine 0.05g one or more; G:L-arginine 0.1g, L-glutamic acid 0.1g, L-proline 0.1g, inositol 0.0025g, vitamin B
20.00015g, nicotinic acid 0.002g, folic acid 0.00006g, vitamin B
120.0000005g, among the pantothenic acid 0.0003g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 40
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 2.5g, L-aspartic acid or aspartate 2.5g, vitamin B
10.01g, vitamin B
60.005g, among the caffeine 0.05g one or more; G:L-arginine 5g, L-glutamic acid 5g, L-proline 5g, inositol 3g, vitamin B
20.02g, nicotinic acid 0.015g, folic acid 0.0004g, vitamin B
120.00001g, among the pantothenic acid 0.02g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 41
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 2.5g, L-aspartic acid or aspartate 2.5g, vitamin B
10.01g, vitamin B
60.005g, among the caffeine 0.05g one or more; G:L-arginase 12 .5g, L-glutamic acid 2.5g, L-proline 2.5g, inositol 1.5g, vitamin B
20.01g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000005g, among the pantothenic acid 0.01g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 42
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 0.05g, L-aspartic acid or aspartate 0.5g, vitamin B
10.0005g, vitamin B
60.0005g, among the caffeine 0.015g one or more; G:L-arginine 0.5g, L-glutamic acid 0.5g, L-proline 0.5g, inositol 0.05g, vitamin B
20.0005g, nicotinic acid 0.005g, folic acid 0.0001g, vitamin B
120.000001g, among the pantothenic acid 0.002g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 43
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 0.05g, L-aspartic acid or aspartate 0.5g, vitamin B
10.0005g, vitamin B
60.0005g, among the caffeine 0.015g one or more; G:L-arginine 3g, L-glutamic acid 3g, L-proline 3 g, inositol 2g, vitamin B
20.015g, nicotinic acid 0.01g, folic acid 0.0003g, vitamin B
120.000008g, among the pantothenic acid 0.015g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 44
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 0.05g, L-aspartic acid or aspartate 0.5g, vitamin B
10.0005g, vitamin B
60.0005g, among the caffeine 0.015g one or more; G:L-arginine 1.8g, L-glutamic acid 1.8g, L-proline 1.8g, inositol 1g, vitamin B
20.008g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000004g, among the pantothenic acid 0.008g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 45
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 3g, L-aspartic acid or aspartate 3g, vitamin B
10.015g, vitamin B
60.008g, among the caffeine 0.05g one or more; G:L-arginine 0.5g, L-glutamic acid 0.5g, L-proline 0.5g, inositol 0.05g, vitamin B
20.0005g, nicotinic acid 0.005g, folic acid 0.0001g, vitamin B
120.000001g, among the pantothenic acid 0.002g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 46
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 3g, L-aspartic acid or aspartate 3g, vitamin B
10.015g, vitamin B
60.008g, among the caffeine 0.05g one or more; G:L-arginine 3g, L-glutamic acid 3g, L-proline 3 g, inositol 2g, vitamin B
20.015g, nicotinic acid 0.01g, folic acid 0.0003g, vitamin B
120.000008g, among the pantothenic acid 0.015g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 47
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 3g, L-aspartic acid or aspartate 3g, vitamin B
10.015g, vitamin B
60.008g, among the caffeine 0.05g one or more; G:L-arginine 1.8g, L-glutamic acid 1.8g, L-proline 1.8g, inositol 1g, vitamin B
20.008g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000004g, among the pantothenic acid 0.008g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 48
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 1.5g, L-aspartic acid or aspartate 1.5g, vitamin B
10.008g, vitamin B
60.004g, among the caffeine 0.025g one or more; G:L-arginine 0.5g, L-glutamic acid 0.5g, L-proline 0.5g, inositol 0.05g, vitamin B
20.0005g, nicotinic acid 0.005g, folic acid 0.0001g, vitamin B
120.000001g, among the pantothenic acid 0.002g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 49
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 1.5g, L-aspartic acid or aspartate 1.5g, vitamin B
10.008g, vitamin B
60.004g, among the caffeine 0.025g one or more; G:L-arginine 3g, L-glutamic acid 3g, L-proline 3 g, inositol 2g, vitamin B
20.015g, nicotinic acid 0.01g, folic acid 0.0003g, vitamin B
120.000008g, among the pantothenic acid 0.015g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 50
Composite for disintoxicating and sobering of the present invention is to be formed by following feedstock production, by weight, and every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g; F: taurine 1.5g, L-aspartic acid or aspartate 1.5g, vitamin B
10.008g, vitamin B
60.004g, among the caffeine 0.025g one or more; G:L-arginine 1.8g, L-glutamic acid 1.8g, L-proline 1.8g, inositol 1g, vitamin B
20.008g, nicotinic acid 0.008g, folic acid 0.0002g, vitamin B
120.000004g, among the pantothenic acid 0.008g one or more.Method for preparing is with other embodiment.
The also available following combination of A to E part replaces in the above all components: A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
The also available following combination of A to E part replaces in the above all components: A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
Embodiment 51
Composite for disintoxicating and sobering of the present invention, the part by weight of glucose and fructose is in its compositions A composition:
Glucose: fructose=0.01～0.99: 0.99～0.01.
Embodiment 52
Composite for disintoxicating and sobering of the present invention, the part by weight of glucose and fructose is in its compositions A composition:
Glucose: fructose=0.2～0.8: 0.8～0.2.
Embodiment 53
Composite for disintoxicating and sobering of the present invention, liquid preparation or electuary or the medicinal tea of said composition for adopting conventional method for preparing to process.Said composition also is added with the existing conventional food additive.
When the value range of certain composition occurring among each embodiment in the description of the present invention, i.e. expression can be in the value range of being explained value arbitrarily.Enumerate concrete numerical value no longer one by one at this.The method for preparing of each embodiment is basic identical, repeats no more here.
Claims (10)
1. composite for disintoxicating and sobering, it is characterized in that: it mainly is to be formed by following feedstock production, by weight, every 100ml:
A: any 5～60g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.1～5g; C:L-alanine 0.1～5g; Any or two kinds of 0.1～5g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.05～5g.
2. composite for disintoxicating and sobering according to claim 1 is characterized in that: said compositions is mainly processed by following raw material, by weight, and every 100ml:
A: any 10～50g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 0.5～3g; C:L-alanine 0.5～3g; Any or two kinds of 0.5～3g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.25～3g.
3. composite for disintoxicating and sobering according to claim 1 is characterized in that: described compositions is mainly processed by following raw material, by weight, and every 100ml:
A: any 15～35g in the mixture of glucose and fructose or high fructose syrup or the Mel; B:L-cysteine 1～2g; C:L-alanine 1～2g; Any or two kinds of 1～2g in D:L-ornithine or the L-glutaminate; E:L-carnitine 0.5～2g.
4. according to claim 1 or 2 or 3 described composite for disintoxicating and sobering, it is characterized in that: said compositions is also added one or more compositions in the following raw material, by weight, and every 100ml:
Taurine 0.01～5g, L-aspartic acid or L-aspartate 0.1～5g, vitamin B
10.00015～0.02g, vitamin B
60.00015～0.01g, caffeine 0.01～0.1g.
5. according to claim 1 or 2 or 3 described composite for disintoxicating and sobering, it is characterized in that: described compositions is also added one or more compositions in the following raw material, by weight, and every 100ml:
Taurine 0.05～3g, L-aspartic acid or L-aspartate 0.5～3g, vitamin B
10.0005～0.015g, vitamin B
60.0005～0.008g, caffeine 0.015～0.05g.
6. according to claim 1 or 2 or 3 described composite for disintoxicating and sobering, it is characterized in that: the part by weight of glucose and fructose is in the said composition components:
Glucose: fructose=0.01～0.99: 0.99～0.01.
7. according to claim 1 or 2 or 3 described composite for disintoxicating and sobering, it is characterized in that: the part by weight of glucose and fructose is in the said composition components:
Glucose: fructose=0.2～0.8: 0.8～0.2.
8. according to claim 1 or 2 or 3 described composite for disintoxicating and sobering, it is characterized in that: said compositions is also added one or more compositions in the following raw material, by weight, and every 100ml:
L-arginine 0.1～5g, L-glutamic acid 0.1～5g, L-proline 0.1～5g, inositol 0.0025～3g, vitamin B
20.00015～0.02g, nicotinic acid 0.002～0.015g, folic acid 0.00006～0.0004g, vitamin B
120.0000005～0.00001g, pantothenic acid 0.0003～0.02g.
9. according to claim 1 or 2 or 3 described composite for disintoxicating and sobering, it is characterized in that: said compositions is also added one or more in the following raw material, by weight, and every 100ml:
L-arginine 0.5～3g, L-glutamic acid 0.5～3g, L-proline 0.5～3g, inositol 0.05～2g, vitamin B
20.0005～0.015g, nicotinic acid 0.005～0.01g, folic acid 0.0001～0.0003g, vitamin B
120.000001～0.000008g, pantothenic acid 0.002～0.015g.
10. according to claim 1 or 2 or 3 described composite for disintoxicating and sobering, it is characterized in that: said compositions is processed liquid preparation or electuary for adopting conventional method for preparing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810237327A CN101766635B (en) | 2008-12-31 | 2008-12-31 | Composite for disintoxicating and sobering |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810237327A CN101766635B (en) | 2008-12-31 | 2008-12-31 | Composite for disintoxicating and sobering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101766635A CN101766635A (en) | 2010-07-07 |
| CN101766635B true CN101766635B (en) | 2012-10-10 |
Family
ID=42499836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810237327A Expired - Fee Related CN101766635B (en) | 2008-12-31 | 2008-12-31 | Composite for disintoxicating and sobering |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101766635B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102987498B (en) * | 2012-08-27 | 2014-08-06 | 南昌大学 | Plant beverage for relieving discomfort after drinking and preparation method thereof |
| CN102813266B (en) * | 2012-08-27 | 2014-06-18 | 南昌大学 | Functional beverage relieving drunk discomfort and preparation method |
| CN102813200A (en) * | 2012-09-06 | 2012-12-12 | 苏州谷力生物科技有限公司 | Health-care product having de-alcoholic effect |
| CN102813267A (en) * | 2012-09-07 | 2012-12-12 | 李强 | Compound de-alcoholic medicine |
| CN103041272A (en) * | 2012-12-26 | 2013-04-17 | 南京恒青楼宇设备有限公司青岛分公司 | Sobering agent |
| CN103404934B (en) * | 2013-08-24 | 2015-07-01 | 江苏阜丰生物科技有限公司 | Hang-over solid beverage containing glutamine and preparation method thereof |
| CN105010937A (en) * | 2015-08-11 | 2015-11-04 | 山东福田药业有限公司 | L-arabinose anti-alcohol pill and preparation method thereof |
| CN105853621A (en) * | 2016-06-02 | 2016-08-17 | 黄美段 | Medicine capable of relieving alcoholism and dispelling effects of alcohol |
| EP3278793A1 (en) * | 2016-08-04 | 2018-02-07 | ppsph. GmbH | Composition for the treatment of veisalgia |
| CN108720013A (en) * | 2018-05-16 | 2018-11-02 | 广东永青生物科技有限公司 | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131187A (en) * | 1995-06-28 | 1996-09-18 | 安俊英 | Beermate and preparation method thereof |
| CN1276704A (en) * | 1997-10-03 | 2000-12-13 | 希格马托制药工业公司 | Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing abuse of alcohol in healthy subjects |
| CN1279111A (en) * | 1999-06-23 | 2001-01-10 | 詹莉 | Nutritive bioenzyme liquor for sobering up and its preparing process |
| CN1291507A (en) * | 1999-10-06 | 2001-04-18 | 赵祖国 | Sobering-up oral liquid |
| CN1631267A (en) * | 2004-11-05 | 2005-06-29 | 湖南金维康生物技术有限公司 | Kudzuvine root drink capable of relieving or neutralizing the effect of alcohol and production technique thereof |
| CN101190025A (en) * | 2006-12-01 | 2008-06-04 | 王颖 | Food for sobering-up, promoting digestion and protecting liver |
-
2008
- 2008-12-31 CN CN200810237327A patent/CN101766635B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131187A (en) * | 1995-06-28 | 1996-09-18 | 安俊英 | Beermate and preparation method thereof |
| CN1276704A (en) * | 1997-10-03 | 2000-12-13 | 希格马托制药工业公司 | Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing abuse of alcohol in healthy subjects |
| CN1279111A (en) * | 1999-06-23 | 2001-01-10 | 詹莉 | Nutritive bioenzyme liquor for sobering up and its preparing process |
| CN1291507A (en) * | 1999-10-06 | 2001-04-18 | 赵祖国 | Sobering-up oral liquid |
| CN1631267A (en) * | 2004-11-05 | 2005-06-29 | 湖南金维康生物技术有限公司 | Kudzuvine root drink capable of relieving or neutralizing the effect of alcohol and production technique thereof |
| CN101190025A (en) * | 2006-12-01 | 2008-06-04 | 王颖 | Food for sobering-up, promoting digestion and protecting liver |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101766635A (en) | 2010-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766635B (en) | Composite for disintoxicating and sobering | |
| CN101574140B (en) | Drink composition with human immunity strengthening and anti-fatigue functions | |
| CN101766715B (en) | Composite for disintoxicating and sobering | |
| CN109601916A (en) | A kind of weight losing meal-replacing composition and preparation method thereof | |
| CN102524883B (en) | Sea cucumber polysaccharide health-care beverage and preparation method thereof | |
| CN101248873A (en) | Drinking food product with sight protection function | |
| CN105876585A (en) | Protein solid beverage and preparation method and application thereof | |
| CN101766672B (en) | Composition for anti-alcohol and sobering | |
| CN101766637B (en) | Composite for disintoxicating and sobering | |
| CN102224891A (en) | Sugar alcohol honey apple jam and preparation method thereof | |
| CN105028868A (en) | Black garlic, black onion and black soybean peptide chewable tablet and preparation method thereof | |
| CN101766636B (en) | Composite for disintoxicating and sobering | |
| CN104336174A (en) | Rhodiola rosea and milk vinegar contained green tea health beverage | |
| CN1692782A (en) | Sour milk pellets with lowering blood-pressure function | |
| JP3899436B2 (en) | Healthy drink with water soluble nucleoprotein | |
| CN101692917A (en) | Brain nourishing beverage | |
| CN1711859A (en) | Fermented milk sheets with auxin | |
| CN101538519A (en) | Pure-natural double-worm health-care rice wine and preparation method thereof | |
| CN101766717B (en) | Composition for disintoxicating and sobering | |
| CN107373260A (en) | A kind of compound antilipemic healthy drinks and preparation method thereof | |
| CN103621871B (en) | Compound amino acid health-care product and preparation method thereof | |
| CN101766716B (en) | Hangover relieving composition | |
| CN103126026A (en) | Beverage for relieving effect of alcohol and preparation method thereof | |
| CN102994299A (en) | Production method of health-care wine | |
| CN101306010B (en) | Function food for reducing the blood sugar and preventing diabetes complicating disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121010 Termination date: 20191231 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |